Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 13/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 4/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 2/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21306829 | 0.88 | CFTR (0.34) | AKT1CTSAAKT2ROCK2ABL1 | |
| SCHEMBL21294930 | 0.83 | IRAK4 (0.39) | — | |
| SCHEMBL21294766 | 0.81 | PIN1 (0.37) | — | |
| SCHEMBL21296540 | 0.81 | PIN1 (0.37) | — | |
| SCHEMBL21294804 | 0.80 | LMNA (0.41) | — | |
| SCHEMBL21296534 | 0.79 | KMT2A (0.38) | — | |
| SCHEMBL21311618 | 0.71 | USP30 (0.41) | CTSACTSVCTSLCTSBCTSS | |
| SCHEMBL21306631 | 0.69 | KAT6A (0.37) | EPHX2 | |
| SCHEMBL21294791 | 0.68 | TAS1R3 (0.35) | — | |
| SCHEMBL23213820 | 0.66 | PORCN (0.49) | CTSACTSVCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | AKT1 2787/4885CTSA 647/4885AKT2 1864/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | AKT1 4575/4885CTSA 3726/4885AKT2 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.